The safe use of cisplatin in hyperthermic isolated limb perfusion systems
- 15 August 1985
- Vol. 56 (4) , 742-744
- https://doi.org/10.1002/1097-0142(19850815)56:4<742::aid-cncr2820560407>3.0.co;2-1
Abstract
A patient presenting with aggressive squamous cell carcinoma successfully received cisplatin chemotherapy via hyperthermic, isolated limb perfusion (renal impairment ruled out systemic use). Human tumor stem cell assay identified cisplatin as the drug of choice and supports the potential benefit of this procedure in single therapeutic situations. The case illustrates the safety of cisplatin and the ability to give large doses of the nephrotoxic drug with no damage to renal function. The potential efficacy over systemic cisplatin has yet to be established except when systemic use is limited from renal dysfunction.This publication has 11 references indexed in Scilit:
- Hyperthermic adjuvant perfusion chemotherapy for stage I malignant melanoma of the extremity with literature reviewCancer, 1983
- Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactionsEuropean Journal of Cancer and Clinical Oncology, 1982
- The Treatment of Stage I Melanoma of the Extremities with Regional Hyperthermic Isolation PerfusionAnnals of Surgery, 1982
- A model of experimental isolation perfusion using cis‐platinumJournal of Surgical Oncology, 1982
- Immunohistochemical demonstration of S 100 protein in malignant melanoma and pigmented nevus, and its diagnostic applicationCancer, 1982
- Tourniquet Infusion Versus Hyperthermic PerfusionCancer, 1982
- Quantitation of Differential Sensitivity of Human-Tumor Stem Cells to Anticancer DrugsNew England Journal of Medicine, 1978
- Soft tissue sarcomas of the extremity: Multidisciplinary therapy employing hyperthermic perfusionThe American Journal of Surgery, 1975
- Chemotherapy of CancerAnnals of Surgery, 1958